Funding Opportunity PAR-21-295 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity of thought in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA.

Funding Opportunity PAR-21-296 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity of thought in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA

Funding Opportunity RFA-CA-21-054 from the NIH Guide for Grants and Contracts. The TBEL program aims to integrate basic and translational cancer research concepts to examine the direct causal relationships and interactions of an early lesion, its microenvironment and host-systemic factors as co-organizers of tumor initiation (or suppression) and malignant progression. The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches. The FOA will utilize the U54 (Specialized Center--Cooperative Agreements) activity code. Each TBEL Center shall have a unique thematic focus and be structured to test hypotheses that bridge basic and translational research in a synergistic and iterative fashion. Collectively, TBEL Centers will operate as a network that will inform future, rationally-design modes of intervention that are founded on strong biological mechanisms and be comprehensive, multi-dimensional, and appropriately tailored to the degree of malignant potential of an early lesion.

Funding Opportunity RFA-CA-21-055 from the NIH Guide for Grants and Contracts. The TBEL program aims to integrate basic and translational cancer research concepts to examine the direct causal relationships and interactions of an early lesion, its microenvironment, and host-systemic factors as co-organizers of tumor initiation (or suppression) and malignant progression. The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches. The responsibilities of the CDMC will be to (1) coordinate consortium-wide meetings and conferences, and cross-consortium collaborative activities; (2) provide statistical and computational analysis support; and (3) establish program data hub for data capture, curation and management, and protocol development and registration. The other scientific unit of the TBEL program will comprise the U54 Centers, which will be structured to efficiently bridge gaps between basic and translational research on early lesions and their microenvironments. This Notice is being provided to allow potential applicants sufficient time to develop a responsive TBEL Coordinating and Data Management Center application. The FOA is expected to be published in May 2021 with an anticipated application due date in October 2021. Details of the planned pre-application webinar will be announced in the Guide after publication of the FOA. The companion notice for the TBEL U54 Centers is: NOT-CA-21-XXX. The FOA will not be restricted to specific early lesion/cancer type(s).

Notice NOT-HL-21-029 from the NIH Guide for Grants and Contracts

Notice NOT-OH-21-011 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-060 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-340 from the NIH Guide for Grants and Contracts

Notice NOT-EB-21-020 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-020 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-015 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-027 from the NIH Guide for Grants and Contracts

Notice NOT-OH-21-012 from the NIH Guide for Grants and Contracts

Notice NOT-NR-21-007 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-059 from the NIH Guide for Grants and Contracts

Notice NOT-HG-21-038 from the NIH Guide for Grants and Contracts

Notice NOT-ES-21-012 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-279 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Funding Opportunity PAR-21-278 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Notice NOT-NS-22-012 from the NIH Guide for Grants and Contracts